Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Oh on the Development of JAK Inhibitors in Myelofibrosis

Stephen Oh, MD, PhD
Published: Friday, Oct 19, 2018



Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Each of the JAK inhibitors, apart from ruxolitinib (Jakafi), has raised concerns over safety, explains Oh. The first of the 3 investigational JAK inhibitors is momelotinib, which seems to improve anemia in a subset of patients. Since Gilead discontinued the development of that agent, Sierra Oncology has acquired the rights to the drug. It looks like it will move forward in development, states Oh.

Pacritinib is another JAK inhibitor that seems to be safe in patients with a low platelet count. The FDA hold on that agent has since been lifted, and there is an ongoing study to determine the lowest dose that can be safely and effectively administered in patients with myelofibrosis, says Oh. Fedratinib, the last JAK inhibitor, had been put on FDA hold due to concerns over Wernicke’s-like encephalopathy syndrome. The FDA hold has also been lifted, and the drug is being redeveloped by Celgene.


Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Each of the JAK inhibitors, apart from ruxolitinib (Jakafi), has raised concerns over safety, explains Oh. The first of the 3 investigational JAK inhibitors is momelotinib, which seems to improve anemia in a subset of patients. Since Gilead discontinued the development of that agent, Sierra Oncology has acquired the rights to the drug. It looks like it will move forward in development, states Oh.

Pacritinib is another JAK inhibitor that seems to be safe in patients with a low platelet count. The FDA hold on that agent has since been lifted, and there is an ongoing study to determine the lowest dose that can be safely and effectively administered in patients with myelofibrosis, says Oh. Fedratinib, the last JAK inhibitor, had been put on FDA hold due to concerns over Wernicke’s-like encephalopathy syndrome. The FDA hold has also been lifted, and the drug is being redeveloped by Celgene.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x